Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 9/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14273420 | 0.86 | TSHR (0.41) | PTPN2PTPN1PTPN6LTA4HTSHR | |
| SCHEMBL6671514 | 0.81 | TSHR (0.52) | LTA4HTSHRPRSS1PRSS2PRSS3 | |
| SCHEMBL10458653 | 0.80 | IDO1 (0.52) | APP | |
| SCHEMBL27123834 | 0.79 | PTPN2 (0.38) | APPPTPN2PTPN1PTPN6LTA4H | |
| SCHEMBL13602773 | 0.79 | TSHR (0.47) | PTPN2PTPN1PTPN6LTA4HTSHR | |
| SCHEMBL10458623 | 0.78 | IDO1 (0.50) | APPPTPN2PTPN1PTPN6 | |
| SCHEMBL10458365 | 0.78 | AGXT (0.50) | APP | |
| SCHEMBL10458632 | 0.78 | IDO1 (0.50) | APP | |
| SCHEMBL7222288 | 0.78 | LTA4H (0.38) | PTPN2PTPN1PTPN6LTA4HTSHR | |
| SCHEMBL3438764 | 0.77 | TSHR (0.64) | LTA4HTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170283-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| CN-113754589-B | Compositions, methods, and systems for synthesizing and using contrast agents | 蓝瑟斯医学影像公司 | 2024-09-27 | — | — | CN | disclosed |
| US-20240100199-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2024-03-28 | — | — | US | disclosed |
| US-11744906-B2 | Compositions, methods, and systems for the synthesis and use of imaging agents | LANTHEUS MEDICAL IMAGING, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| CN-113754589-A | Compositions, methods, and systems for synthesis and use of contrast agents | 蓝瑟斯医学影像公司 | 2021-12-07 | — | — | CN | disclosed |
| CN-107311935-B | Compositions, methods, and systems for synthesis and use of contrast agents | 蓝瑟斯医学影像公司 | 2021-10-08 | — | — | CN | disclosed |
| US-20200230264-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2020-07-23 | — | — | US | disclosed |
| EP-3653621-A1 | APPARATUS FOR SYNTHESIZING THE IMAGING AGENT 4-CHLORO-2-(1,1-DIMETHYLETHYL)-5-[[4-[[2-(FLUORO-[18F])ETHOXY]METHYL]PHENYL]METHOXY]-3(2H)-PYRIDAZINONE (FLUORPIRIDAZ [18F]) | Lantheus Medical Imaging, Inc. (US) | 2020-05-20 | — | — | EP | disclosed |
| US-10500293-B2 | Compositions, methods, and systems for the synthesis and use of imaging agents | LANTHEUS MEDICAL IMAGING, INC. (US) | 2019-12-10 | — | — | US | disclosed |
| EP-2882719-B1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AS IMAGING AGENTS FOR DETECTING MYOCARDIAL PERFUSION | LANTHEUS MEDICAL IMAGING INC (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20180318456-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2018-11-08 | — | — | US | disclosed |
| US-9919064-B2 | Compositions, methods, and systems for the synthesis and use of imaging agents | LANTHEUS MEDICAL IMAGING, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-9713651-B2 | Compositions, methods, and systems for the synthesis and use of imaging agents | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20170202984-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170151353-A9 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-06-01 | — | — | US | disclosed |
| US-9555138-B2 | — | — | 2017-01-31 | — | — | US | disclosed |
| US-20150196672-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2015-07-16 | — | — | US | disclosed |
| EP-2882719-A2 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | Lantheus Medical Imaging, Inc. (US) | 2015-06-17 | — | — | EP | disclosed |
| WO-2014026079-A2 | COMPOSITIONS, METHODS, AND SYSTEMS OF THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2014-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150196672-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | TNNI3, FABP3, TNNT2 | APP 1621/4885PTPN2 3309/4885PTPN1 3382/4885 |
| US-20250170283-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | APP 673/4885PTPN2 3633/4885PTPN1 3478/4885 |
| US-20170151353-A9 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | TNNI3, FABP3, TNNT2 | APP 1621/4885PTPN2 3309/4885PTPN1 3382/4885 |
| US-20180318456-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | APP 673/4885PTPN2 3633/4885PTPN1 3478/4885 |
| US-20200230264-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | APP 673/4885PTPN2 3633/4885PTPN1 3478/4885 |
| US-10500293-B2 | Compositions, methods, and systems for the synthesis and use of imaging agents | FABP3, TNNI3, TNNT2 | APP 673/4885PTPN2 3633/4885PTPN1 3478/4885 |
| US-20240100199-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | APP 673/4885PTPN2 3633/4885PTPN1 3478/4885 |
| US-11744906-B2 | Compositions, methods, and systems for the synthesis and use of imaging agents | FABP3, TNNI3, TNNT2 | APP 673/4885PTPN2 3633/4885PTPN1 3478/4885 |
| US-20170202984-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | APP 673/4885PTPN2 3633/4885PTPN1 3478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.